A revolution in glucose monitoring

The potential of non-invasive technology is powerful

Partners highlights


Over a decade of ground-up, proprietary technology development by a team of experts with deep subject matter expertise in Raman spectroscopy, optical engineering and glucose monitoring


A substantial portfolio of clinical trial outcome assets to support a move toward commercialization


Compelling health economics with consumer acceptance and user experience at the forefront


Technology designed so that an average person can use it

The TGM opportunity

Non-invasive can be a transformative technology for tens or hundreds of millions. Needles and the fear of having to draw blood from oneself can be a major hurdle faced by people who want to understand their glucose levels.1  RSP Systems has developed a patented, clinically tested, non-invasive and non-intrusive glucose monitoring technology system that has the potential to be a game changer.

Note: The GlucoBeam touch glucose monitoring technology system is an investigations system not yet FDA cleared for commercial sale or use.  Any subsequent variants of the technology or alterations to the base technology could require additional clearance or approval (510K, De Novo or PMA), depending on alterations to the base technology and desired claims or intended use. 

1. Anxiety associated with self monitoring of capillary blood glucose, Br J Diabetes Vasc Dis 2014;14:60-63

The power of light

Market potential for touch glucose monitoring

The market for a willingly accepted technology to manage health is enormous.

The applicability of non-invasive technology is massive, covering those who are on a path to disease and want to start monitoring, as well as those who desire to optimize or simply know the state of their health. The GlucoBeam technology system offers a means for people to know the effect of different foods, exercise, stress, and other factors on their  glucose levels – without the penalty of invasive measurement.

In the US alone, 70% of all adults are overweight or obese. Globally, more than 1.9 billion adults worldwide were overweight in 2016, including 650 million obese. The World Health Organization estimates that obesity tripled worldwide between 1975 and 2016. Obesity across the world shows the wide-reaching opportunity for touch glucose monitoring.

The link between obesity and other diseases is undeniable. Monitoring technologies that require a doctor’s visit and doctor’s prescription leave a vast gap in accessibility, meaning that huge volumes of people have no idea of the effect of different foods, exercise, stress, etc. on their glucose levels.

Technologies designed for consumer use at home or in an everyday environment are also much more likely to gain acceptance and usage – a key opportunity.

Obesity Data by Country

Country% ObesePopulation# Obese
United States42%332,915,073 141,155,991
China6%1,444,216,107 89,541,399
India4%1,393,409,038 54,342,952
Brazil22%213,993,437 47,292,550
Mexico29%130,262,216 37,645,780
Russia23%145,912,025 33,705,678
Egypt32%104,258,327 33,362,665
Turkey32%85,042,738 27,298,719
Iran26%85,028,759 21,937,420
Pakistan9%225,199,937 19,367,195
Indonesia7%276,361,783 19,068,963
United Kingdom28%68,207,116 18,961,578
Nigeria9%211,400,708 18,814,663
Germany22%83,900,473 18,709,805
South Africa28%60,041,994 16,991,884
France22%65,426,179 14,132,055
Argentina28%45,605,826 12,906,449
Iraq30%41,179,350 12,518,522
Saudi Arabia35%35,340,683 12,510,602
Global Data# Obese
Top 20 Countries662,489,824
Rest of World285,764,312
Global Total1,004,492,376

Potential user acceptance of TGM technology


RSP’s initial research shows possible user acceptance of monitoring glucose via non-invasive technology. RSP conducted an internal survey to gauge potential acceptance. Among people with prediabetes or who were at risk for diabetes, 90% indicated positively to consideration of monitoring at home with non-invasive touch glucose monitoring.1

1 Data based on a survey of 961 people (607 in the US and 354 in Europe), conducted in 2020 by a third party.
Seeing the effect of different foods
on glucose levels may be valuable.

Potential applications

Potential applications of touch glucose monitoring can include consumer products, metabolic health, health & wellness, weight loss, and others based on technical or commercial partner targets, including those of interest to investors. Our future roadmap for technology iteration includes leveraging user data and advanced software to increase the technology’s performance, extending the applicability to larger populations, as well as an aggressive path to technology miniaturization.

All potential new variations of the technology may require additional clearance or approval. RSP’s R&D team is able to provide expertise to partners toward that achievement.

Clinical investigations

The value of a health technology is limited until clinically proven to be as safe and effective for use on humans. A sequence of trials must be conducted on the intended user population before being cleared and becoming eligible for sale. To work toward meeting these regulations, RSP has pursued research & development through a series of studies, testing and clinical trials over a decade.

The technology system has yielded clinical, technical and user acceptance outcomes that will support future use. Our clinical assets include a total of more than 700 people tested in more than 15 investigations in Europe, including our ongoing investigation.

RSP has participated in scientific conferences and presented scientific posters/abstracts at ATTD, DT, DTM and ADA. Our current clinical plan focuses on a consumer application of the technology.

Partner with RSP

TGM technology has potential as a stand-alone investment and/or in conjunction with future digital health partners. Digital health investment hit at a new all-time high in 2020, with over $14 billion invested across 440 deals, a perfect storm in the alignment of investors, consumers, employers, and markets1.

Our non-invasive technology is uniquely positioned to be a potential differentiator among digital health offerings.

For inquiries regarding potential investment, co-development, technology licensing, or other future commercial partnership, please contact us.